News

The pharmaceutical industry is no stranger to long-term investments in research and development (R&D). One of India’s prominent pharmaceutical companies, Wockhardt, witnessed an unprecedented stock surge, climbing fivefold due to the success of a unique molecule developed over 25 years. 

In July, Wockhardt’s new drug Zaynich, an antibiotic targeting highly resistant infections, helped treat a challenging infection in a young cancer patient in California. News of Zaynich’s successful trials is already boosting Wockhardt’s stock price, with some investors making long-term bets on the company.

Wockhardt’s shares have struggled, underperforming the Nifty 50 by over 150% over the past decade, impacting its reputation as an investment. However, its recent breakthrough antibiotic drug has sparked interest from mutual funds and prominent investors. 

Mutual funds and high-net-worth investors like Rekha Jhunjhunwala were among the first to spot the opportunity. The stock has surged 5x in a year to over INR 1,100 per share, yet the company’s financial struggles persist. It has reported losses for 11 straight quarters, its return ratios have declined for over a decade, and its sales growth remains highly inconsistent.

For Wockhardt chairman Habil Khorakiwala, it was a wait spanning over two decades. His first antibiotic, WCK771, began its journey in 2000, with Zaynich standing out as a promising lead that his scientists were hopeful about.

What is Zaynich

It is an antibiotic designed to combat bacterial infections that have developed significant resistance to other treatments. Known as WCK5222 or Zaynich, this unassuming drug has captured the attention of investors. Wockhardt now has an opportunity to reclaim its former glory.

WCK 5222: Zaynich

The Financial Impact: Why Wockhardt’s Stock Surged

• Stock Market Reaction: Wockhardt’s stock performance reflected strong investor sentiment, rallying five times its previous value as news of the molecule’s success spread. This reaction highlights the market’s confidence in the drug’s revenue potential.
• Attraction for Institutional Investors: A breakthrough drug with regulatory approval attracts institutional investors. This spike indicates heightened interest, setting Wockhardt apart from its competitors in the pharmaceutical sector.
• Regulatory Milestones: According to reports, Wockhardt plans to secure Indian regulatory approval for Zaynich by March next year. Phase three clinical trials are expected to conclude by early 2026, and a global launch could follow by mid-2026.
• Breakthrough in Antibiotic Innovation: Zaynich combines Wockhardt’s drug, zidebactam, with cefepime, a Bristol-Myers Squibb antibiotic, and is one of the rare treatments effective against various difficult-to-treat pathogens discovered in the last five decades.
• A Timely Solution to Antibiotic Resistance: In a world where antibiotic misuse is rampant, fatal infections from resistant pathogens are becoming a leading cause of death. Zaynich provides critical hope, especially for patients facing severe infections after complex surgeries.
• Expansive Market Opportunity: According to Khorakiwala, this drug could benefit approximately 700,000 patients in the US alone, and it has an even larger market in India, impacting over 1.1 million. Source: Economic Times

Challenges and Future Prospects

Wockhardt is conducting a global phase three clinical study for Zaynich, indicating advanced human testing across multiple countries. Successful completion of this study could lead to registrations and marketing authorizations within the next two years.

Pricing Strategy

• When Zaynich becomes available in India, Wockhardt plans to price it at a 75%—80% discount compared to US rates, which range from USD 8,000 to USD 10,000 per treatment course.

Impact of Antimicrobial Resistance (AMR)

• In the US, there are over 2.8 million AMR cases annually, resulting in approximately 48,000 deaths.
• Wockhardt projects that by 2050, AMRs could cause over 8 million deaths worldwide and impact the global economy by USD 100 trillion.

Market Potential

• Zaynich represents a significant advancement in managing bacterial infections, particularly against carbapenem-resistant strains.
• Competitors include Pfizer’s Avycaz, Zavicefta, and Shionogi’s Fetroja.
• The global market for these drugs is expected to reach USD 1 billion, with potential sales for Zaynich projected at around USD 500 million in a few years.

Cautions and Considerations

• Zaynich will not be a first-line treatment due to the need for careful assessment to avoid misuse and resistance.
• Challenges may arise in achieving rapid adoption among doctors. Experts emphasize the importance of effective marketing and distribution for Wockhardt to capitalize on its research investments.
• Alliances with global players are recommended for better licensing and negotiation outcomes.

Competition Landscape

Orchid Pharma achieved a breakthrough with enmetazobactam (Exblifep) earlier this year, receiving FDA approval for complicated urinary tract infections. Companies are focusing on promising molecules to inhibit beta-lactamases, reducing the frequency of AMR development.

Bugworks is another player with promising antibiotic research, particularly with drug BWC0977, which is effective against various life-threatening infections. Other companies like Rempex Pharmaceuticals and Merck are also pursuing new treatment options.

Wockhardt’s Opportunity

Wockhardt faces significant opportunities in the market, but these come with considerable risks. The company’s track record in risk management has been inconsistent.

Historical Challenges

• In the early 2000s, Wockhardt accumulated debt by spending USD 453 million on three international acquisitions.
• The company suffered losses of INR 555 crore from foreign exchange and derivatives during the global financial crisis of 2008, which severely impacted its economic health.
• By 2012, Wockhardt resolved its debt issues through loan restructuring and the sale of hospital assets. It experienced a brief period of recovery, with sales exceeding INR 5,500 crore in FY13.

Recent Struggles

• Following this peak, Wockhardt entered a downward trend, with all seven manufacturing plants facing scrutiny from US regulatory authorities between 2014 and 2019.
• Additional debt restructuring and partial monetization of non-core businesses have kept the company afloat during these challenging years.
• In 2020, Wockhardt sold part of its domestic branded business, including a manufacturing plant in Baddi, Himachal Pradesh, to Dr. Reddy’s for INR 1,850 crore.

Current Risk-Reward Assessment

• With Wockhardt’s stock price already reflecting expectations of potential sales from Zaynich, the current risk-reward ratio appears unfavorable, indicating limited upside potential.
• The company must improve profitability before Zaynich’s launch to justify the current market valuation.

Source: Economic Times

Conclusion

The 25-year journey to develop this molecule speaks volumes about the dedication, innovation, and resilience required to thrive in the pharmaceutical industry. Wockhardt’s success could catalyze more investment in patient-centered R&D, reshaping market dynamics and inspiring confidence in long-term scientific pursuits.

Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & the certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

FAQ

Have you been tracking the movement of Reliance Industries Ltd (RIL) shares? Monday marked a significant moment as RIL shares turned ex-bonus for its sixth and largest bonus issue in Indian history—a 1:1 issue that has doubled shareholders’ stakes. What does this mean for investors, and how has the share price shifted following this major development?

The Bonus Issue and Its Impact on Shareholders

Reliance Industries recently declared a 1:1 bonus issue ahead of its Annual General Meeting (AGM), granting shareholders one bonus share for each share held. This latest bonus issue, the sixth in RIL’s history, is a milestone for the company and its investors. With each bonus issue, shareholders effectively double their holdings without making additional investments. Such an issue, especially on this scale, can profoundly affect stock liquidity, investor sentiment, and long-term market performance.

When RIL shares opened on Monday morning, they were adjusted for the bonus issue, reflecting a starting price of Rs 1,338—a 49.61% drop from Friday’s close of Rs 2,655.45. However, this apparent drop was only an adjustment, with the share price showing a modest gain of 0.77% on an adjusted basis.

How a Bonus Issue Affects Share Price and Shareholding

In financial terms, a bonus issue increases the number of outstanding shares in the market. As a result, the stock price adjusts downward in proportion to the bonus share ratio to keep the company’s overall valuation the same. This adjustment can make shares appear cheaper, often enhancing liquidity and opening doors for more investors. However, it also impacts the company’s free reserves and surplus, as they are adjusted to account for the additional shares.

This bonus issue was RIL’s first since 2017 when the stock was priced at Rs 725.65. Since then, RIL’s stock has surged by nearly 270%, delivering robust returns for its investors. This remarkable growth has led the stock to its latest adjusted value of Rs 2,655.45 just before Monday’s ex-bonus trading session.

Key Historical Context: RIL’s Bonus Issuance Track Record

Reliance Industries has a history of issuing bonuses at strategic points. The company’s previous bonus issuance was in 2009, when shares were issued in the same 1:1 ratio, and the stock turned ex-date on November 26 of that year. Notably, the 1997 issuance was also a 1:1 issue. Before this, RIL offered bonuses in the 6:10 ratio in 1983 and the 3:5 ratio in 1980. Each issuance has played a role in elevating the stock’s liquidity and rewarding shareholders, helping Reliance grow into one of India’s most valuable companies.

Moreover, RIL has proactively offered rights issues, with five offerings, the latest one issued in May 2020. In a strategic move in July 2023, RIL completed the demerger of Jio Financial Services Ltd, creating additional value streams within its expanding corporate structure.

RIL’s Market Influence Following the Ex-Bonus Adjustment

RIL’s influence on the broader Nifty 50 index cannot be overstated. As shares adjusted for the 1:1 bonus on Monday, Reliance’s stock was a key contributor to the index’s gains, which rebounded after five consecutive days of losses. Monday’s session saw RIL add approximately 20 points to the Nifty, indicating its significant weight on the index and broader market sentiment.

Despite recent market headwinds, RIL’s stock rebounded from oversold levels on Friday. The Relative Strength Index (RSI) dipped to 29.5, indicating that the stock was near an oversold threshold (an RSI below 30 generally suggests this status). By Monday, the stock had rallied, trading at Rs 1,349—up by 1.7% from its adjusted opening price, showing resilience and renewed investor confidence.

Broader Market Trends and RIL Share’s Position

The past month has been challenging for the Indian stock market, with BSE-listed companies losing market capitalization worth ₹41 lakh crore since September 27, when the Nifty reached a record high of 26,277. Amid this market turbulence, Reliance shares declined by 13%, resulting in a loss of Rs. 2.77 lakh crore in market capitalization. However, RIL’s shares have shown stability year-to-date, up by 2.53%, in contrast to the BSE Sensex’s rise of 9.87% over the same period.

Analyst Sentiment: A Mixed Yet Optimistic Outlook for RIL

Market analysts have mixed but generally positive expectations for RIL’s future performance. According to PL Capital Institutional Equities, RIL’s core refining and petrochemical businesses may face challenges soon due to a muted refining outlook. Still, gas production is expected to hold steady at 28-30 mmscmd with realizations of around $10/MMBtu. Furthermore, Jio’s Average Revenue Per User (ARPU) saw a 7% quarter-on-quarter increase, and projections suggest continued growth bolstered by recent tariff adjustments.

RIL’s retail business is expected to maintain steady performance. JM Financial notes that RIL’s strategic focus on renewable energy and the green sector will likely strengthen its position over the coming years. They also highlight the potential for revenue growth in Jio and retail operations within the next 3-4 years.

What Lies Ahead for Reliance Industries

Reliance Industries continues to adapt and expand, both domestically and internationally. The company’s ventures into retail, telecommunications, and green energy signal a forward-looking strategy that positions it for long-term growth. RIL has committed an impressive Rs 75,000 crore to its renewable energy initiatives, which could transform India’s clean energy landscape.

Additionally, analysts believe that the potential demerger of RIL’s retail and Jio Platforms, combined with the expansion of green energy initiatives, could strengthen the company’s value and increase shareholder wealth. 

Conclusion

Reliance’s recent 1:1 bonus issue marks an important chapter in its history, reaffirming its role as a cornerstone of the Indian stock market. For current shareholders, the 1:1 bonus reflects RIL’s strategy to reward its investors while maintaining market liquidity. As RIL diversifies and adapts to market demands, its role within the Nifty 50 remains pivotal. Whether RIL can sustain the momentum of its impressive returns in the future is yet to be seen.

Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & the certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Are you planning to buy a new car this festive season? If so, you might be surprised to learn that car dealerships across India are grappling with an unprecedented inventory pile-up. 

The Federation of Automobile Dealers Associations (FADA) recently reported that retail car sales in India plummeted by 18.81% in September, creating significant financial pressure on dealerships.

The overall inventory has reached an all-time high, with over 790,000 unsold vehicles worth approximately INR 79,000 crore, representing a supply lasting 80 to 85 days. This situation poses serious challenges to the automotive retail sector, raising concerns about its resilience amid persistent economic pressures and fluctuating demand.

Why the Retail Cars Overstock?

The Indian automotive market, once a beacon of growth, is now facing a period of uncertainty. Several factors have contributed to the current situation:

• Aggressive Dispatches: Automakers, eager to meet production targets, have been aggressively dispatching vehicles to dealerships, even in the face of slowing demand.
• Weak Consumer Sentiment: Rising interest rates, inflation, and geopolitical tensions have dampened consumer sentiment, reducing demand for new cars.
• Shifting Market Dynamics: The market is witnessing a shift towards premium and SUV segments, while demand for entry-level and mid-segment cars has softened.
• Production Challenges: Supply chain disruptions and component shortages have impacted production schedules, leading to an inventory build-up.

The market is also experiencing the impact of frequent new model launches, especially in the compact SUV category, which has led to competition among models and further inventory accumulation. As a result, older models are now piling up in dealerships, unable to keep pace with consumer preferences for the latest offerings. Source: Economic Times

Which Car Brands Are Most Affected?

While the entire industry grapples with inventory issues, some brands are more affected than others. Maruti Suzuki, India’s largest carmaker, is facing a significant inventory buildup, especially for models like the Baleno and Grand Vitara. Hyundai and Mahindra also deal with higher-than-normal inventory levels, particularly for specific models.

1 Mahindra & Mahindra

Mahindra dealers currently hold an average of 50 days’ worth of inventory, with popular models like the Bolero, Scorpio-N, and XUV700 experiencing varying demand across different regions. For example, urban dealerships have seen higher stocks of rural-favorite Bolero models, while tier-II and tier-III cities are witnessing higher supplies of Scorpio-N and XUV700 due to their popularity in metro regions.

2. Kia India

Kia dealers have managed to avoid high discount pressures, holding an average inventory of around 1.5 months. Models like the Seltos continue to perform well, while the recently launched Carnival MPV has drawn attention with a six-month waiting period. The South Korean brand appears less impacted by inventory challenges than other major automakers.

3. Maruti Suzuki India

Maruti Suzuki, India’s largest carmaker, deals with average dealership inventories of 60 days. However, some models like the Baleno and the Grand Vitara carry higher stock levels of up to 90 days. The premium Nexa outlets, which usually offer higher dealer margins, are experiencing flat growth due to high inventory levels.

Conversely, Arena outlets selling high-demand models like the Swift and Brezza have seen better performance, with Brezza carrying a waiting period of 15 days. However, internal competition has also impacted Maruti’s sales; the Swift has cannibalized 20% of Baleno’s sales, while Brezza has similarly affected Grand Vitara sales.

4. Tata Motors

Tata Motors is currently offering substantial discounts on several models, with the Tata Safari carrying a cash discount of INR 25,000 and a price drop of INR 1.8 lakh. The Harrier offers a similar cash discount and a price reduction of INR 1.6 lakh. The Nexon iCNG and electric models have drawn strong demand for Tata dealerships. In October, Tata adjusted its targets to reduce inventory; the company reduced its wholesale targets while raising retail goals to help dealers clear stock from an initial 90-day inventory level at the start of the month to 45 days by month-end.

5. Hyundai Motor India

Hyundai dealerships operate with inventories of 45 to 60 days, though the flagship Creta SUV is an exception, remaining a fast-mover without any discounts or significant stock buildup. The newly launched Alcazar has shown promise in the market, but models like the Exter are seeing slower demand, with inventory levels around two months. According to Samir Choudhry of Trident Automobiles in Bengaluru, a dealer’s business judgment often influences inventory decisions, but rapid stock build-up can lead to financial stress. Source: Economic Times

The Impact on Dealers

This oversupply of vehicles has put significant financial pressure on car dealerships. With unsold inventory piling up, dealers face challenges in managing cash flow and meeting their financial obligations. They are resorting to heavy discounts and promotional offers to clear the stock, which can erode profit margins. Many automakers, like Tata Motors, have restructured targets to adjust the stock burden on dealerships, while others are focusing on clearing older models through increased promotions.

New model launches and special editions are also being leveraged to drive showroom traffic, offering potential buyers an incentive to consider other available models alongside these fresh releases. Vehicles like the 2024 Maruti Suzuki Swift, Hyundai Alcazar, and Mahindra 3XO, as well as special editions from multiple automakers, are generating significant interest. However, most new models are in high demand and do not suffer from inventory overhang.

Outlook for Indian Car Dealerships

Dealerships hope the Diwali season will clear most of the current stock, and FADA is optimistic about improved sales continuing into November. However, the overall sentiment remains cautious, as several external factors have impacted auto sales over recent months, including a prolonged election season, extreme weather, and regional floods.

The Road Ahead

To address the overstocking issue, automakers and dealers may need to adopt a more cautious approach to production and inventory management. This could involve adjusting production schedules, offering more attractive financing options, and implementing innovative marketing strategies to stimulate demand.

As consumers, this presents an opportunity to negotiate better deals and secure significant discounts on new cars. However, it’s essential to carefully consider your needs and budget before making a purchase. The Indian auto industry is undoubtedly going through a challenging phase. However, it can emerge stronger and more resilient with the right strategies and adjustments.

*Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as recommendation or investment advice by Research & Ranking. We will not be liable for any losses that may occur. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.